Literature DB >> 25935522

Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.

Hui-Min Chen1, Kai Yu2, Xiao-yan Tang2, Zhao-shi Bao3, Tao Jiang3, Xiao-Long Fan4, Xiao-Wei Chen5, Xiao-Dong Su6.   

Abstract

PTPRZ1-MET (ZM) proteins are a group of fusion proteins identified in human gliomas by high-throughput transcriptome sequencing. ZM fusions are associated with poor prognosis in afflicted glioma patients and mediate oncogenic effects in assays. In this study, we show that ZM-carrying patients have increased hepatocyte growth factor receptor (MET) mRNA expression levels induced by fusion with receptor-type tyrosine-protein phosphatase zeta (PTPRZ1). Furthermore, ZM fusions preserve fundamental properties of wild-type MET with respect to processing and dimerization, and enhance phosphorylation in an hepatocyte growth factor (HGF)-dependent and independent manner. Our findings suggest that ZM induces gliomas through elevated expression and phosphorylation of the MET oncoprotein.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dimerization; Expression level; Fusion gene; Hepatocyte growth factor receptor; Phosphorylation; Receptor-type tyrosine-protein phosphatase zeta

Mesh:

Substances:

Year:  2015        PMID: 25935522     DOI: 10.1016/j.febslet.2015.04.032

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

Review 1.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

2.  Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas.

Authors:  Zheng Zhao; Fanlin Meng; Wen Wang; Zheng Wang; Chuanbao Zhang; Tao Jiang
Journal:  Sci Data       Date:  2017-03-14       Impact factor: 6.444

3.  Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.

Authors:  A-L Zeng; W Yan; Y-W Liu; Z Wang; Q Hu; E Nie; X Zhou; R Li; X-F Wang; T Jiang; Y-P You
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 4.  Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment.

Authors:  Tao Xu; Hongxiang Wang; Xiaoquan Huang; Weiqing Li; Qilin Huang; Yong Yan; Juxiang Chen
Journal:  Transl Oncol       Date:  2018-03-20       Impact factor: 4.243

5.  Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.

Authors:  Rui-Chao Chai; Xing Liu; Bo Pang; Yu-Qing Liu; Jing-Jun Li; Yang-Fang Li; Zheng Zhao; Jiang Du; Zhao Shi Bao; Tao Jiang
Journal:  Cancer Sci       Date:  2021-11-30       Impact factor: 6.716

6.  In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma.

Authors:  Ainhoa Hernandez; Ana Maria Muñoz-Mármol; Anna Esteve-Codina; Francesc Alameda; Cristina Carrato; Estela Pineda; Oriol Arpí-Lluciá; Maria Martinez-García; Mar Mallo; Marta Gut; Sonia Del Barco; Oscar Gallego; Marc Dabad; Carlos Mesia; Beatriz Bellosillo; Marta Domenech; Noemí Vidal; Iban Aldecoa; Nuria de la Iglesia; Carmen Balana
Journal:  Sci Rep       Date:  2022-08-24       Impact factor: 4.996

7.  Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction.

Authors:  Zenghui Qian; Yiming Li; Zhiyan Sun; Xing Fan; Kaibin Xu; Kai Wang; Shaowu Li; Zhong Zhang; Tao Jiang; Xing Liu; Yinyan Wang
Journal:  Aging (Albany NY)       Date:  2018-10-22       Impact factor: 5.682

8.  The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective.

Authors:  Saba Ahmadi; Pattara Sukprasert; Rahulsimham Vegesna; Sanju Sinha; Fiorella Schischlik; Natalie Artzi; Samir Khuller; Alejandro A Schäffer; Eytan Ruppin
Journal:  Nat Commun       Date:  2022-03-25       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.